BRIEF—Nuvig names Joanne Quan CMO

California-based Nuvig Therapeutics, a private biotech company developing novel therapeutics to restore immune homeostasis and treat chronic autoimmune diseases, has announced the appointment of Joanne Quan as chief medical officer (CMO).

Dr Quan has more than 25 years of experience advancing drug candidates in all stages of development, from pre-clinical compounds to marketed products, according to Nuvig.

“Joanne has a passion and commitment to developing new therapies for patients with high unmet medical needs and has a successful track record in advancing novel drug candidates for a wide range of therapeutic areas, including autoimmune disorders and rare and orphan diseases,” said Pamela Conley, chief executive and co-founder of Nuvig.

Prior to joining Nuvig, Dr Quan was the CMO of Modis Therapeutics. She has also held positions at Eiger Biopharmaceuticals, InterMune, Arena Pharmaceuticals, Bayhill Therapeutics and Genentech, among others.